Siwen Hu-lieskovan

Biography

 Dr. Siwen Hu-Lieskovan is a physician-scientist conducting clinical and laboratory research focused in immunotherapy for advanced solid malignancies. Her research includes: Understand the antitumor activity of immune modulatory agents, and develop single agent or combination immunotherapy clinical trials in solid tumors. Investigate cancer immune resistant mechanisms in the tumor microenvironment and how combination strategies can improve immunotherapy outcome in solid tumors (especially melanoma and lung cancer) by studying preclinical models and patient derived samples from clinical trials (received Daniel D. Von Hoff Innovative Protocol Award, Tower Research Foundation Grant; Book Chapter on Lung Cancer and Immunotherapy in press). Develop cell-based immunotherapy clinical trials, i.e. adoptive cell transfer therapy with T-cell receptor engineered lymphocytes, dendritic cell cancer vaccines, and the combination of cell-based and checkpoint inhibitor-based immunotherapeutics. Investigate the combination of targeted therapy and immunotherapy for long-term control of metastatic melanoma (one research paper published in Science Translational Medicine and featured in NIH Director’s Blog, two manuscripts submitted; review paper published in JCO; Abstract accepted as podium presentation at 2014 ASCO annual meeting and as Merit Award recipient, and ASCO YIA recipient). Targeted therapy and nanoparticle based delivery systems

Research Interest

 edicine, Hematology and Oncology